See more : Melcor Developments Ltd. (MODVF) Income Statement Analysis – Financial Results
Complete financial analysis of Mindset Pharma Inc. (MSSTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mindset Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Curro Holdings Limited (COH.JO) Income Statement Analysis – Financial Results
- FLIGHT SOLUTIONS Inc. (3753.T) Income Statement Analysis – Financial Results
- Kyowa Electronic Instruments Co., Ltd. (6853.T) Income Statement Analysis – Financial Results
- cBrain A/S (CBRAIN.CO) Income Statement Analysis – Financial Results
- Remi Edelstahl Tubulars Limited (REMIEDEL.BO) Income Statement Analysis – Financial Results
Mindset Pharma Inc. (MSSTF)
About Mindset Pharma Inc.
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 3.91M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.91M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.39M | 2.22M | 0.00 | 0.00 |
| General & Administrative | 13.09M | 6.24M | 45.62K | 13.95K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.09M | 6.24M | 45.62K | 13.95K |
| Other Expenses | -33.41K | -71.37K | 0.00 | 0.00 |
| Operating Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Cost & Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 44.53K | 22.26K | 171.86K | 161.14K |
| EBITDA | -16.53M | -5.32M | -58.15K | -13.95K |
| EBITDA Ratio | -423.29% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.58M | -5.35M | -58.15K | -13.95K |
| Operating Income Ratio | -424.43% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -33.41K | -6.31M | 25.04K | 0.00 |
| Income Before Tax | -16.61M | -11.65M | -33.10K | -13.95K |
| Income Before Tax Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.12M | 0.00 | 0.00 |
| Net Income | -16.61M | -11.65M | -33.10K | -13.95K |
| Net Income Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| EPS | -0.18 | -0.20 | 0.00 | 0.00 |
| EPS Diluted | -0.18 | -0.20 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 90.06M | 57.66M | 66.14M | 66.14M |
| Weighted Avg Shares Out (Dil) | 90.06M | 57.66M | 66.14M | 66.14M |
Mindset Pharma and PharmAla complete first sale of pharmaceutical-grade psilocybin into growing Australian market via sales partnership
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) said PharmAla Biotech (CSE:MDMA) Holdings Inc has completed the first sale of a quantity of Mindset's pharmaceutical grade (cGMP) psilocybin under the companies' exclusive sales agreement. The psilocybin is being purchased by Reset Mind Sciences...
Mindset Pharma receives another allowance for US patent application expanding composition of matter for Family 1 psilocybin analogs
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) told investors that the US Patent and Trademark Office has granted allowance for another of its Family 1 patent applications, number 17/743,718, titled ‘Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders'. The...
Mindset Pharma receives allowance for US patent application covering lead psychedelic therapeutic candidate
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) told investors that the US Patent and Trademark Office (USPTO) has granted allowance for its patent application number 17/833,341, titled 'Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders'. The drug discovery...
Mindset Pharma to Participate in Upcoming Conferences in December 2022
TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with...
Mindset Pharma spotlights recent achievements ahead of ‘even more exciting 2023' in shareholder update
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) said its goal of bringing best-in-class optimized psychedelic medicines to patients in need is important and achievable, as the company highlighted its recent accomplishments and expressed its excitement for 2023 and beyond. In a letter to...
Mindset Pharma and PharmAla Biotech forge exclusive sales agreement
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF), which is focused on developing next-generation psychedelic and non-psychedelic drugs to treat neuropsychiatric disorders, revealed that it has forged an exclusive sales agreement with PharmAla Biotech (CSE:MDMA) Holdings Inc. The Vancouver-based drug discovery company said...
Mindset Pharma presents data showing its psilocin prodrug is better tolerated than psilocybin
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has developed a psilocin prodrug that may be just as effective at treating depression as psilocybin but better tolerated. The company's chief scientific officer, Joseph Araujo, recently presented findings at Neuroscience 2022, a conference hosted...
Mindset Pharma chooses pair of psychedelic drug candidates to move Family 2 program forward
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) said it has chosen a pair of psychedelic drug clinical candidates from its Family 2 program of potential mental health medications, to advance its program to IND enabling studies. The lead candidate MSP-2020, and back-up drug...
Mindset Pharma provides strategic intellectual property license to Cybin for preclinical psychedelic drug research
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has announced an exclusive licensing agreement for Cybin Inc to acquire intellectual property rights for a subset of Mindset's preclinical compounds. Under the terms of the agreement, biopharmaceutical company Cybin will license intellectual property related to...
Mindset Pharma to advance lead psychedelic drug candidate MSP-1014 into Phase 1 first-in-human trial
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) said it is finalizing its Phase 1 first-in-human clinical trial plan for its lead psychedelic drug candidate MSP-1014 for the treatment of major depressive disorder after receiving scientific advice from the UK Medicines and Healthcare...
Source: https://incomestatements.info
Category: Stock Reports